Trial Search Results
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Stanford is currently not accepting patients for this trial.
Jean Yuh Tang
Collaborator: Menlo Therapeutics Inc.
- Drug: VPD-737
- Other: Placebo
- Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
- Chronic liver or renal disease
Ages Eligible for Study
13 Years - N/A
Genders Eligible for Study